Foresite Capital Management IV’s Rhythm Pharmaceuticals RYTM Stock Holding History

Foresite Capital Management IV’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-234,482	Closed	-$5.06M	–	15
2019 Q3	$5.06M	Sell	234,482 -235,000	-50%	-$5.04M	1.64%	15
2019 Q2	$10.3M	Buy	469,482 +64,456	+16%	+$1.63M	2.92%	13
2019 Q1	$11.1M	Buy	405,026 +5,026	+1%	+$144K	3.99%	10
2018 Q4	$10.8M	Sell	400,000 -296,903	-43%	-$8.21M	4.94%	8
2018 Q3	$20.3M	Sell	696,903 -25,000	-3%	-$790K	6.66%	7
2018 Q2	$22.6M	Buy	721,903 +521,903	+261%	+$14.3M	7.69%	7
2018 Q1	$3.98M	Buy	200,000 +25,000	+14%	+$664K	1.65%	16
2017 Q4	$5.09M	Buy	+175,000	New	+$4.63M	3.57%	10

Other funds holding RYTM

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Foresite Capital Management IV's RYTM Position: Q4 2019 in Review

Foresite Capital Management IV sold out of Rhythm Pharmaceuticals (RYTM) in Q4 2019, closing a stake of 234,482 shares — an estimated $5.06M sold.

Foresite Capital Management IV first reported a position in RYTM in Q4 2017 and held it in 8 quarters. The position peaked at $22.6M in Q2 2018. 89 funds tracked by Wall St. Rank hold RYTM as of Q4 2019.

Foresite Capital Management IV reported no remaining Rhythm Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
Foresite Capital Management IV sold 234,482 Rhythm Pharmaceuticals shares in Q4 2019, an estimated $5.06M.
Foresite Capital Management IV first reported a position in Rhythm Pharmaceuticals in Q4 2017 and held it in 8 quarters.
Foresite Capital Management IV's Rhythm Pharmaceuticals position peaked at $22.6M in Q2 2018.
89 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q4 2019.

Based on Foresite Capital Management IV's 13F filing for Q4 2019, filed 14 Feb 2020.